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Abstract
Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) was overexpressed and purified from Escherichia coli. Mouse monoclonal
antibodies (mAbs) were prepared that react with EBNA1. Eleven high affinity mAbs were recovered. Nine mAbs are isotype
IgG (all subisotype IgG1) and two mAbs are isotype IgM. All mAbs react strongly with EBNA1 in an ELISA assay while only
one mAb (designated 1EB6) fails to react in a Western blot assay. The epitopes for these mAbs were mapped to seven
different regions, providing good coverage of the entire EBNA1 protein. The mAbs had differing affinity for an EBNA1/DNA
complex with four mAbs able to supershift the complex completely. All mAbs can immunoprecipitate EBNA1 from E. coli
overexpressing EBNA1. A modified ELISA assay, termed ELISA-elution assay, was used to screen for mAbs that release EBNA1
in the presence of a low molecular weight polyhydroxylated compound (polyol) and a nonchaotropic salt. MAbs with this
property, termed polyol-responsive (PR)-mAbs, allow gentle elution of labile proteins and protein complexes. Four mAbs are
polyol-responsive with two showing usefulness in gentle immunoaffinity chromatography. Purification with these PR-mAbs
may be useful in purifying EBNA1 complexes and elucidating EBNA1-associated proteins. This panel of anti-EBNA1 mAbs will
advance the study of EBV by providing new tools to detect and purify EBNA1.
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Introduction
Epstein-Barr virus (EBV) is a gamma-herpesvirus that is the
causative agent of infectious mononucleosis and a risk factor in a
variety of malignancies, including Burkitt’s lymphoma and
nasopharyngeal carcinoma [1,2]. EBV nuclear antigen 1 (EBNA1)
is the only viral protein found in all EBV-related malignancies [3].
EBNA1, a 641-amino acid protein, plays an important role in
maintaining EBV in the host cell and has been implicated in host
cell immortalization. It is the only viral factor required in trans for
efficient replication of the EBV genome during latency [3] and
regulates transcription at multiple viral promoters [4–6].
The N-terminus of EBNA1 consists primarily of a 239-amino
acid domain comprised of a Glycine-Glycine-Alanine (GGA)
repeat region. An EBNA1 derivative (referred to as 1553),
encoding only fifteen residues from the GGA repeat region,
maintains the ability to support replication and transcription in cell
culture [7] and the ability to immortalize B cells [8]. Amino acids
64–89 comprise a transcriptional activation domain [9]. The C-
terminus of EBNA1 contains a dimerization domain and a DNA
binding domain. EBNA1 also contains two linking regions (LR1
and LR2), which allow EBNA1 dimers bound to DNA to associate
with other bound EBNA1 dimers and thereby loop intervening
DNA sequences in cis or link two DNA molecules in trans [10,11].
Though the protein domain structure is well described, many
fundamental aspects of EBNA1 biology remain poorly understood.
We have recently developed vectors and procedures for readily
expressing and purifying various EBNA1 constructs in E. coli,
described in [12], allowing us to generate a diverse library of
EBNA1-specific murine monoclonal antibodies (mAbs). Mice were
injected with increasing amounts of EBNA1 protein, and the
spleen cells were fused to myeloma cells to generate hybridoma
cell lines. Four fusions have been completed, resulting in eleven
high affinity mAbs. Most mAbs are subisotype IgG1 molecules and
react with epitopes located throughout the EBNA1 protein. We
screened the mAbs for specific reactivity to EBNA1 by enzyme-
linked immunosorbent assay (ELISA) and Western blot analysis,
and analyzed their ability to supershift an EBNA1/DNA complex.
We tested each mAb for its ability to immunoprecipitate (IP)
EBNA1 from whole cell extract. Although immunoaffinity
chromatography (IAC) is a powerful purification technique, it
usually requires a high concentration of denaturing reagents and/
or extreme pH to dissociate the antigen-antibody interaction. As a
result, inactive, denatured proteins are recovered and protein
complexes are difficult to maintain. Our lab has pioneered work
using polyol-responsive mAbs (PR-mAbs) in IAC. PR-mAbs allow
gentle elution through the use of a low molecular weight
polyhydroxylated compound (polyol), like propylene glycol (PG)
or ethylene glycol, and a nonchaotropic salt, like NaCl or
ammonium sulfate (AS). Typically, only approximately 10–20%
of all mAbs tested have this property [13].
PR-mAbs are especially useful in purifying proteins that retain
biological activity and structural integrity. PR-mAbs allow
purification in sufficient yield, purity, and homogeneity to allow
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in protein complexes, PR-mAbs provide a method of gently
eluting the protein resulting in recovery of functional proteins and
multi-subunit complexes that are structurally intact and biologi-
cally active (for reviews see [15,16]). Many groups have been able
to isolate protein complexes using PR-mAbs and determine the
interacting partners of their protein of interest [13,14,17–19]. Four
anti-EBNA1 mAbs showed polyol-responsiveness in our ELISA-
elution assay with two shown to be useful in purifying EBNA1 in
one chromatographic step using PR-mAb IAC technology.
Materials and Methods
Reagents and buffers
All reagents were obtained from Sigma Chemical (St. Louis,
MO) unless otherwise noted. TE buffer contains 50 mM Tris-HCl
and 0.1 mM EDTA, pH 7.9. BLOTTO contains 1% nonfat dried
milk in phosphate-buffered saline (PBS).
Plasmids
1553 encodes a fully functional EBNA1 variant that contains 15
residues of the GGA repeat present between amino acids 90 and
325 of EBNA1 encoded by the B95-8 strain of EBV [20]. All other
derivatives used in this study also contain this deletion. 1553 will
be referred to as EBNA1. See schematic in Fig. 1A. 3015
additionally lacks amino acids 64–89. Both plasmids were ligated
into the pET22b expression vector (Novagen, Madison, WI) as
described in [12]. 1891 contains two deletions: 1) N-terminus to
amino acid 39 and 2) amino acid 90 to 377. This derivative retains
LR1, nuclear localization sequence (NLS), and the DNA-binding
and dimerization domains. 2728 and 2729 lack amino acids 397–
418 and 395–430, respectively. All of the plasmids listed above
were gifts from Dr. Bill Sugden. LR1GAx2 is a construct that
contains two copies of the LR1 domain with 18 amino acids from
the GGA repeat region in the center. This construct is cloned into
the pET28b expression vector (Novagen). 1553, 3015, and
LR1GAx2 were all expressed in E. coli as described in [12].
Cells
293 cells are derived from human embryonic kidney cells [21]
and were grown in Dulbecco’s modified Eagle’s medium
(Invitrogen) supplemented with 10% fetal bovine serum, 200 U/
ml penicillin, and 200 mg/ml streptomycin. All cells were grown at
37uC in a humidified 5% CO2 atmosphere.
Figure 1. Epitope mapping of the N-terminal anti-EBNA1 mAbs. A) The constructs used to analyze mAb reactivity. Full length EBNA1 is
shown at the top, numbered according to the B95-8 EBV strain. LR-1 and LR-2 (linking regions 1 & 2) are designated, as well as the GGA repeat region
between amino acids 90 and 325. The C-terminus is largely composed of the DNA-binding and dimerization domain. 1553 encodes functionally
wildtype EBNA1, but lacks the majority of the GGA stretch. The remaining EBNA1 derivatives are derived from the 1553 construct and thus carry the
GGA deletion. B) 1891 was transfected into 293 cells and whole cell extract was analyzed by Western blot. The first lane in each series contains
purified 1553, the second lane is untransfected 293 whole cell extract (mock), and the third lane is whole cell extract from cells transfected with the
1891 plasmid. Equal concentrations of purified mAbs were used to probed the Western blots. C) Plasmids 2728 and 2729 were transfected into 293
cells and whole cell extract was analyzed by Western blot. NT, not transfected. Equal concentrations of purified mAbs were used to probe the
Western blots. D) Purified EBNA1 derivatives were analyzed by Western blot for mAb reactivity. Equal concentrations of mAb 1EB12 or mAb 1EB14
were used to probe the Western blots. E) Summary of the anti-EBNA1 mAb epitopes. The schematic shows endogenous EBNA1 protein, numbered
according to the B95-8 strain of EBV, and the domain structure. The lines represent the various epitope regions and the mAbs that interact in that
area are written below. MW is molecular weight.
doi:10.1371/journal.pone.0004614.g001
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Plasmids 1891, 2728, and 2729 were transiently transfected into
293 cells. 5 mg of DNA and 5 mg of empty vector DNA were
combined in 500 ml Opti-Mem (Invitrogen) and mixed with 40 mg
polyethyleneimine (PEI) in 500 ml Opti-Mem. The solution was
added to 10 ml of cells, and incubated at 23uC for 20 min. Cells
were allowed to grow 48 h at 37uC and harvested.
Hybridomas and mAbs
For the isolation of hybridomas that produce EBNA1-specific
mAbs, Ni-NTA-purified recombinant EBNA1 was prepared as
described in [12] and injected into Balb/c ByJ mice (Jackson
Laboratory, Bar Harbor, ME) according to the following schedule:
four female mice were each injected on day 1 with 5 mg, on day 14
with 10 mg, and on day 28 with 20 mg. The first injection was
contained in Freund’s complete adjuvant, and subsequent
injections were contained in Freund’s incomplete adjuvant. Each
injection (100 ml) was administered subcutaneously (SQ) and
intraperitoneally (IP). Animals were bled on day 1 to obtain the
pre-immune sera for a negative control and day 42 to test for
reactivity with EBNA1 antigen in an enzyme-linked immunosor-
bent assay (ELISA). All sera showed a titer of greater than 1:6400
when assayed by ELISA. One mouse was injected 90 days after
the third injection with 60 mg EBNA1 contained in PBS,
administered IP. Three days later, the animal was sacrificed,
and the spleen cells were fused with NS-1 and SP2/0 myeloma
cells using standard hybridoma techniques [22]. Fusions were
screened by ELISA and Western blot assay. Hybridomas were
cloned twice by limiting dilution. Isotyping was performed using
an ELISA-based kit (HyClone, Logan, UT). All animal protocols
were approved by the University of Wisconsin-Madison School of
Medicine and Public Health Animal Use and Care Committee.
Purification of mAbs
IgG1 mAbs were grown in Celline flasks (IBS Integra
Biosciences, Chur, Switzerland) according to manufacturer
instructions and purified as follows. To remove albumin, mAb
sample was brought to 45% saturated ammonium sulfate, mixed
on ice for 20 min, and incubated at 4uC for 18 h. The sample was
collected by centrifugation (12,000 g for 20 min at 4uC). The
pellet was resuspended in antibody buffer (50 mM Tris-HCl,
25 mM NaCl, pH 6.9) and dialyzed into antibody buffer at 4uC
for 18 h. Any precipitate was removed and the supernatant was
applied to a DEAE cellulose (Whatman, Maidstone, England)
column equilibrated in antibody buffer at 23uC. The flowthrough
contains purified mAb. MAb 1EB14 did not flow through the
DEAE column, but eluted from the column with 500 mM NaCl.
MAb 1EB14 was additionally purified using a 15-ml PorosHQ50
anion exchange chromatography column. The sample was diluted
to 25 mM NaCl, loaded, washed with 25 mM NaCl, and eluted
over a 25 mM–1 M NaCl salt gradient in TE buffer.
Preparation of mAb-Sepharose
mAb-Sepharose was prepared as described previously [13]. MAb
was dialyzed into coupling buffer (0.1 M NaHCO3, 0.5 M NaCl,
pH 8.3) overnight at 4uC. Purified mAb (2.5 mg/ml swollen
Sepharose) was conjugated to cyanogen bromide (CNBr)-activated
Sepharose 4B. CNBr-activated Sepharose was re-swollen in 1 mM
HCl and rinsed with coupling buffer. Sepharose and mAb were
mixed end-over-end at 23uC for 2 h and collected on a sintered
glass filter. MAb-Sepharose was mixed with blocking agent (6%
ethanolamine in coupling buffer, pH 8.0) for 2 h at 23uC. Four sets
of alternating washes of coupling buffer and acetate buffer (0.1 M
sodium acetate, 0.5 M NaCl, pH 4.0) were used to remove non-
covalently bound protein from the resin. MAb-Sepharose was
stored in TE+0.02% NaN3 at 4uC. This resin can be used multiple
times if treated and stored as described [15,16].
Preparation of mAb-rProteinA beads
MAbs were dialyzed into crosslinking buffer (50 mM sodium
borate, 3 M NaCl, pH 9.0) and added to rProteinA-agarose beads
(Repligen, Waltham, MA). The reaction proceeded with gentle
shaking for 1 h at 23uC. The beads were washed with crosslinking
buffer. 20 mM dimethyl pimelimidate-2HCl (DMP) crosslinker
(Pierce, Rockford, IL) was added and incubated with the beads for
30 min at 23uC. 50 mM Tris-HCl, pH 7.9 was used to wash the
beads and quench the reaction over a 2 h incubation at 23uC. The
resin was stored in PBS+0.02% NaN3 at 4uC.
Table 1. Summary of anti-EBNA1 murine mAbs.
mAb Isotype Epitope WB WB’ ELISA PR-mAb IP Supershift
1EB2 IgG1 451–641 Y Y 1.160.04 Y
a ++ 2
1EB3 IgM 1–458 Y Y 1.160.07 N NYT NYT
1EB6 IgG1 458–641 N N 2.160.05 N ++ ++
1EB12 IgG1 40–65 Y Y* 1.460.04 N ++ 2
1EB14 IgG1 418–430 Y Y 1.460.13 N ++ ++
2EB3 IgM 458–641 N N 1.460.04 Y NYT NYT
3EB7 IgG1 458–641 Y Y 1.960.08 Y ++ +
3EB8 IgG1 377–395 or 430–458 Y Y 1.460.01 N ++ 2
3EB9 IgG1 458–641 Y Y 1.760.06 N ++ ++
3EB13 IgG1 377–395 or 430–458 Y Y 1.660.01 Y ++ /2
3EB16 IgG1 458–641 Y Y 1.960.13 N ++ ++
WB: Western blot, WB’: Western blot signal with endogenous EBNA1, ELISA: the average ELISA signal when adding equal concentrations of purified mAb to an EBNA1-
coated well, PR-mAb: polyol-responsive mAb, IP: immunoprecipitation, Supershift: ability to bind to EBNA1/DNA complex and change its mobility during non-
denaturing gel electrophoresis, NYT: not yet tested. Epitope was determined as in Fig. 1.
*particularly high affinity for endogenous EBNA1.
aresponsive to salt alone.
doi:10.1371/journal.pone.0004614.t001
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ELISA-elution assays were performed as described
[13,15,16,19]. Microtiter plates were coated with 50 ng of EBNA1
in a 50 ml volume of PBS at 23uC with shaking for 2 h. The plate
was blocked with 200 ml per well of BLOTTO at 4uC overnight.
The plate was washed 3 times with PBST (PBS+0.1% Tween 20).
Purified antibody diluted 1:1000 in BLOTTO or undiluted cell
supernatant from hybridoma cell culture was added to the wells
and incubated for 1 h at 23uC. The plate was washed three times
with PBST. Polyol elution buffer (TE buffer plus various
combinations of propylene glycol and ammonium sulfate) was
added to each well and allowed to incubate for 20 min. The plate
was washed three times with PBST. Remaining primary antibody
was detected using an enzyme-conjugated secondary antibody and
the appropriate substrate.
Electrophoresis and Western blotting
Proteins were separated by electrophoresis using 4–12% Bis/
Tris NuPAGE polyacrylamide gels (Invitrogen). Western blots to
detect EBNA1 expressed in E. coli were prepared as described
previously [12], with a secondary antibody (goat anti-mouse IgG)
conjugated to alkaline phosphatase and the 5-bromo-4-chloro-3-
indolyl phosphate and nitroblue tetrazolium (BCIP/NBT) reagent
as substrate. Western blots to detect EBNA1 from lymphoma cell
lines used the secondary antibody goat anti-mouse IgG, human
serum adsorbed, conjugated to horseradish peroxidase (KPL,
Gaithersburg, MD) and enhanced chemiluminescent (ECL)
substrate (Pierce) for detection. Prestained molecular weight
markers (Multimark, Invitrogen) were included on all gels.
MagicMark molecular weight markers (Invitrogen) were included
on the gels for ECL detection.
Figure 2. Ability of mAbs to bind EBNA1/DNA complex. MAbs were tested by EMSA to determine binding efficiency to a pre-formed EBNA1/
DNA complex. Purified EBNA1 protein was bound to a
32P-labelled oligonucleotide encoding one palindromic EBNA1 binding site. Equal
concentrations of purified mAb were added to each reaction and allowed to incubate. The ability of the mAbs to shift the EBNA1/DNA complex was
analyzed by gel electrophoresis. The first lane does not include any protein. The second lane contains only DNA and EBNA1. MAbs are listed by the
last number in their name.
doi:10.1371/journal.pone.0004614.g002
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To test the applicability of these mAbs to immunoprecipitate
(IP) EBNA1 from E. coli whole cell extract, a frozen cell pellet
(7.5 mg wet weight) from 5 mls of induced culture was
resuspended in 100 mlT E +0.1 M NaCl. Cells were lysed by
sonication (4 rounds of 30 s bursts on ice). Cell debris and
inclusion bodies were removed by centrifugation (27,000 g for
20 min at 4uC). The soluble fraction was added to 40 ml of 50%
(w/v) mAb-Sepharose slurry, previously equilibrated two times in
5 column volumes (CV) of TE+0.1 M NaCl. Cell extract and resin
were mixed at 23uC for 1 h. The resin was washed twice with 5
CV TE+0.1 M NaCl and twice with 5 CV of TE+0.5 M NaCl. 1
CV of 26sodium dodecyl sulfate (SDS) sample buffer plus heating
at 95uC for 4 min was used to elute the bound proteins. Results
were analyzed by Western blot using 2B4 rat anti-EBNA1 mAb
[23] for the E. coli-expressed samples.
Immunoaffinity purification of EBNA1 using polyol-
responsive mAbs
Frozen cell pellet (1.5 g wet weight) from 1 L of induced E. coli
culture was resuspended in 20 ml TE+0.1 M ammonium sulfate
(AS). Cells were lysed by sonication (4 rounds of 30 s bursts on ice).
Cell debris and inclusion bodies were removed by centrifugation
(27,000 g for 20 min at 4uC). The soluble fraction was applied to a
4-ml column of either 1EB2- or 3EB7- Sepharose. The columns
were washed with 2.5 CV of TE+0.1 M AS and either 2.5 CV of
TE+40% propylene glycol (PG) for 1EB2 or 2.5 CV of TE+0.5 M
AS for 3EB7. EBNA1 was eluted with TE+0.75 M AS+40% PG
from both columns.
Electrophoretic mobility shift assay
Plasmid 3304 was used to generate a 176-bp oligonucleotide
encoding a 16-bp palindromic EBNA1 binding site of sequence
GGTAGCATATGCTACC [24]. Five hundred femtomoles of the
double-stranded DNA probe was end-labeled by T4 polynucleo-
tide kinase (New England Biolabs, Ipswich, MA) with 2 pmol
[c-
32P]ATP in a volume of 20 ml. Ten femtomoles of end-labeled
probe was incubated with 40 ng EBNA1 in a total volume of
15 ml. The reaction was carried out in 16EMSA buffer (20 mM
Hepes, pH 7.6, 40 mM KCl, 1 mM MgCl2, 1 mM EDTA, and
10% glycerol) with 20 mg/ml poly(dI-dC) (GE Healthcare) for
15 min at 23uC. For the mAb supershift assays, 50 ng mAb was
added, and the reactions were allowed to incubate at 23uC for an
additional 15 min. The reactions were subjected to electrophoresis
using a 3–8% Tris/acetate NuPAGE gel (Invitrogen) at 125 V at
4uC for 3.5 h. Gels were transferred to Whatman paper, dried at
80uC for 1 h, and analyzed by PhosphoImager Screen analysis
using a Storm Imager (Molecular Dynamics, Sunnyvale, CA).
Results and Discussion
EBNA1 mAb generation
The E. coli-expressed EBNA1 protein was used to immunize
mice to generate EBNA1-specific mAbs. Mice were injected with
increasing amounts of EBNA1 protein, sacrificed, and the spleen
cells were fused to myeloma cells to produce hybridoma cell lines.
Four fusions were completed isolating 11 high affinity mAbs, two
are isotype IgM and the remaining 9 are subisotype IgG1. Table 1
summarizes the characteristics of these EBNA1-reactive mAbs.
The mAbs were screened for specific reactivity to EBNA1 by
ELISA and Western blot analysis (Table 1). All mAbs reacted with
full-length EBNA1 by Western blot, except mAb 1EB6 (data not
shown). This mAb reacted strongly in the ELISA assay, but showed
no affinity for EBNA1 on a Western blot. The structure of EBNA1
may be important to the binding of mAb 1EB6 since the ELISA
assayretainsmore ofthe native structure than Westernblot analysis.
Also, the IgM mAb 2EB3 did not react specifically to EBNA1 on a
Western blot, which is commonly seen with the IgM isotype.
MAbs were also tested for reactivity with endogenous EBNA1
from the 721 lymphoblastoid cell line (LCL) (data not shown). This
EBNA1 protein carries the full GGA stretch and, presumably,
post-translational modifications that may influence the binding of
mAbs to the protein. Most mAbs did not have high enough affinity
to detect the small amount of EBNA1 present in this sample. MAb
1EB12 had an especially strong interaction with endogenous
EBNA1, followed by mAb 1EB14.
Epitope mapping
Anti-EBNA1 mAbs were first tested for their ability to bind a C-
terminal derivative of EBNA1, containing amino acids 458–641.
MAbs 1EB6, 3EB7, 3EB9, and 3EB16 all bound this derivative by
ELISA and/or Western blot analysis. MAb 1EB2 had an
intermediate binding affinity for this derivative when compared
to full-length EBNA1, as seen in ELISA (data not shown).
However, mAb 1EB2 bound as strongly to a derivative encoding
amino acids 451–641 as it did to full-length EBNA1. These data
indicate that only a portion of the epitope for mAb 1EB2 is
contained within amino acids 458–641 or additional N-terminal
amino acids are necessary to stabilize the epitope. C-terminal mAb
1EB6 also maps to residues 458–641 by ELISA, but does not react
in a Western blot suggesting it interacts with a different region
within this peptide. It is likely that there are several different
epitopes contained within this group; more testing of various C-
terminal EBNA1 derivatives would be required to map these
epitopes more precisely.
Figure 3. Immunoprecipitation of EBNA1. E. coli-expressed EBNA1
(,50 kDa) was isolated from whole cell extract by mixing with equal
quantities of mAb-rProteinA-agarose resin. Reactions were allowed to
incubate for 1 h, washed to remove nonspecifically bound proteins, and
eluted with SDS sample buffer. MW is molecular weight. The Western
blot was probed with rat mAb 2B4 [23].
doi:10.1371/journal.pone.0004614.g003
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terminal half of EBNA1 (1EB12, 1EB14, 3EB8 and 3EB13),
Western blot analysis was performed on a variety of EBNA1
derivatives. These constructs are shown in Fig. 1A. All mAbs
reacted with 3015, which carries a deletion of unique region 1
(UR1), amino acids 65–89. All mAbs also reacted with 1891 which
carries two deletions: 1) N-terminus to amino acid 39 and 2) amino
acid 90 to 377 (Fig. 1B). MAbs 1EB12, 3EB8, and 3EB13 reacted
with both 2728, which carries a deletion of amino acids 397–418,
and 2729, carrying a deletion of amino acids 395–430 (Fig. 1C).
MAb 1EB14, however, only reacted with 2728, not 2729. The
epitope for mAb 1EB14 is most likely contained within amino
acids 418–430, however, the deletion of amino acids 395 and 396
may remove an essential residue of the mAb 1EB14 epitope.
MAbs 3EB8 and 3EB13 react either with amino acids 377–395 or
430–458.
mAb1EB12isuniqueinthatitistheonlymAbtobindLR1GAx2,
a derivative that encodes two LR1 peptides (amino acids 40–90)
bordering an 18-amino acid stretch of the GGA repeat (Fig. 1D).
Since mAb 1EB12 interactswith 1891 (lacking any sequence from the
GGA repeat) and 3015 (deleting half of LR1), the epitope must be
located within amino acids 40–65. EBNA1 is methylated on the
Figure 4. Polyol-responsiveness of anti-EBNA1 mAbs. A) ELISA-elution assay results to determine polyol-responsiveness. A standard ELISA
protocol was performed with the addition of an intermediate step. After the anti-EBNA1 mAbs are bound to the EBNA1-coated well, either a control
buffer (TE: 50 mM Tris-HCl, pH 7.9+0.1 mM EDTA) or a salt-polyol buffer (AS/PG: TE buffer+1 M ammonium sulfate+40% propylene glycol or NaCl/PG:
TE buffer+1 M NaCl+40% propylene glycol) was added to the wells. MAbs that are polyol-responsive will have lower affinity for their antigen in the
salt-polyol buffer which will result in a decrease in signal after the addition of a secondary antibody and the ELISA substrate. The experiment was
done in triplicate. B) Detailed analysis of mAb 3EB7 response to various combinations of ammonium sulfate (AS) and propylene glycol.
doi:10.1371/journal.pone.0004614.g004
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mAb 1EB12 has a much stronger reactivity to endogenous EBNA1
compared to the rest of the mAbs while the reactivity to E. coli-
expressed EBNA1 is similar to the rest of the mAbs, it is possible that
the modification of these arginine residues increases the affinity of
mAb 1EB12 for its epitope. MAb 1EB3 has not been tested
extensively, but its epitope is contained within amino acids 1–458.
This panel of anti-EBNA1 mAbs provides good coverage of the
entire EBNA1 protein. A summary of the epitopes for the anti-
EBNA1 mAbs is shown in Fig. 1E and Table 1.
Ability of mAbs to bind EBNA1/DNA complex
To test the ability of these mAbs to bind to an EBNA1/DNA
complex, an electrophoretic mobility shift assay (EMSA) was
utilized (Fig. 2). The DNA probe contained one high affinity
binding site for EBNA1. An EBNA1/DNA complex was formed
and then the mAbs were added. The same experiment was done
first forming the EBNA1/mAb complex and then adding DNA,
but the results were the same suggesting that either the half-life of
these interactions is shorter than the incubation time allowed or
the formation of these complexes does not interfere with each
other such that everything can bind simultaneously.
The EBNA1/DNA complex alone migrated and formed a
doublet that was consistently seen. The doublet may have been a
result of DNA and/or EBNA1 sample heterogeneity. MAbs 1EB6,
1EB14, 3EB9, and 3EB16 were able to supershift the EBNA1/
DNA complex very strongly, with mAbs 1EB6, 3EB9, and 3EB16
shifting all of the EBNA1/DNA complex. MAbs 3EB13 and 3EB7
were able to supershift the complex to an intermediate level. MAb
3EB7 had a nonspecific interaction with the DNA probe (data not
shown) that resulted in the dark smear below the supershift band.
MAbs 1EB2 and 1EB12 showed a smear above the EBNA1/DNA
complex bands suggesting that the mAbs are able to bind the
complex weakly, dissociating randomly throughout electrophore-
sis, therefore resulting in a shifted protein smear. Incubation with
mAb 3EB8 resulted in a very light supershift band.
Immunoprecipitation of EBNA1
The ability of the mAbs to immunoprecipitate (IP) E. coli-
expressed EBNA1 was tested. MAb resin was made by crosslinking
the mAb to rProteinA-agarose beads. First, EBNA1 was
overexpressed in E. coli and whole cell extract was prepared.
The mAb resin was mixed with the soluble fraction of the whole
cell extract, washed with lysis buffer followed by a more stringent
wash with high salt buffer, and protein was eluted by SDS sample
buffer and heating. Resin alone did not bind any EBNA1 protein,
but all mAbs were able to IP EBNA1 (Fig. 3). MAb 3EB13
purification was not as strong when the salt in the second wash was
increased to 500 mM NaCl, suggesting the interaction between
this mAb and EBNA1 is weakened by higher salt.
Polyol-responsiveness of mAbs
A unique property of a few mAbs, termed polyol-responsiveness,
was first described in our lab [15,16]. These mAbs maintain a high
affinity and tight interaction with their antigen during loading and
washing, but release under special gentle conditions.
To determine which mAbs have this characteristic, we
performed a modified enzyme-linked immunosorbent assay
(ELISA), termed ELISA-elution assay. This procedure follows a
typical protocol for an ELISA assay, but adds a salt-polyol buffer
incubation step. The primary mAb is released if the salt-polyol
buffer reduces its affinity for antigen. Unbound primary mAb is
washed away and detection of bound mAb by a secondary
antibody is reduced.
Figure 5. Immunoaffinity chromatography using PR-mAbs. The soluble fraction of whole cell extract from E. coli overexpressing EBNA1 was
added to A) mAb 1EB2-Sepharose column and B) mAb 3EB7-Sepharose column, washed, and eluted with TE+0.75 M AS+40% PG. Coomassie blue
stained gels are shown.
doi:10.1371/journal.pone.0004614.g005
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MAbs 1EB2, 2EB3, 3EB7, and 3EB13 were found to have a
reduced signal when incubated with a salt-polyol buffer containing
either 1 M AS+40% PG or 1 M NaCl+40% PG (Fig 4A). MAb
1EB12 shows a typical ELISA-elution assay result of a mAb that is
not polyol-responsive. In general, a mAb is considered polyol-
responsive if the signal drops to 50% of the TE buffer signal when
incubated with polyol buffer. The signal for PR-mAbs 1EB2,
2EB3, 3EB7, and 3EB13 dropped to 25%, 30%, 33% and 63% of
the original signal, respectively. PR-mAb 3EB13 did not drop to
the 50% threshold; however, our lab has shown that this decrease
might still allow for efficient immunoaffinity purification (R.
Burgess, personal communication). A detailed analysis of PR-mAb
3EB7 polyol-responsiveness is shown in Fig. 4B. An increase in salt
alone did not decrease the signal significantly. PR-mAb 1EB2 is
sensitive to salt alone, without any polyol.
As discussed previously [13,19], we do not know the mechanism
of the polyol/salt elution or the physicochemical properties that
make certain mAbs polyol-responsive.
EBNA1 immunoaffinity chromatography using PR-mAbs
Utilizing PR-mAbs in immunoaffinity chromatography (IAC)
allows for purification of active, nondenatured proteins and
protein complexes. The utility of PR-mAbs 1EB2 and 3EB7 to
purify EBNA1 from whole cell extract was tested. EBNA1 was
overexpressed in E. coli and the whole cell extract was applied to a
4-ml column of the appropriate immunoaffinity resin. Both
columns were washed with lysis buffer. 1EB2-Sepharose was then
washed with 40% PG alone while 3EB7-Sepharose was washed
with TE+0.5 M AS. 1EB2-Sepharose was not washed with the
more stringent salt conditions due to its salt sensitivity. EBNA1 was
eluted from both columns with TE+0.75 M AS+40% PG. Both
purifications show an efficient single-step immunoaffinity chro-
matography procedure resulting in high yield and purity of
EBNA1 (Fig. 5).
Since EBNA1 has no known independent enzymatic activity, it
most likely carries out its numerous functions through interaction
with other proteins. Using these PR-mAbs to gently elute EBNA1
complexes would provide a new, powerful method to elucidate
EBNA1-associated proteins. This group of PR-mAbs covers three
epitope groups. Use of a set of PR-mAbs against EBNA1 would
allow better coverage of the protein and, presumably, recover a
range of EBNA1 complexes that may have been missed when
probing with only one mAb, due to possible competition between
the mAb and certain interacting partners.
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